Publication:
Monocyte to High-Density Lipoprotein Ratio in Patients With Arteritic and Non-Arteritic Anterior Ischaemic Optic Neuropathy

dc.authorscopusid57192211319
dc.authorscopusid25633265700
dc.authorscopusid8540670700
dc.contributor.authorKocak, N.
dc.contributor.authorYeter, V.
dc.contributor.authorGüngör, I.
dc.date.accessioned2020-06-21T12:18:11Z
dc.date.available2020-06-21T12:18:11Z
dc.date.issued2020
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Kocak] Nurullah, Department of Ophthalmology, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Yeter] Volkan, Department of Ophthalmology, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Güngör] Inci Ulu, Department of Ophthalmology, Ondokuz Mayis Üniversitesi, Samsun, Turkeyen_US
dc.description.abstractThe purpose of this study was to evaluate the monocyte to high-density lipoprotein (HDL) ratio (MHR) in patients with arteritic anterior ischaemic optic neuropathy (A-AION) and non-arteritic anterior ischaemic optic neuropathy (NA-AION). A total of 98 subjects were included in the study. Patients were divided into three groups: 16 patients with A-AION regarded as group one; 41 patients with NA-AION regarded as group two and 41 healthy subjects regarded as the control group. The MHR was calculated in all participants and compared between the patient and control groups. The mean age of subjects with A-AION, NA-AION and the control group were 75.9 ± 8.9 years, 67.1 ± 9.2 years, and 66.6 ± 6.7 years, respectively. Baseline clinical characteristics, such as diabetes mellitus and hypertension, were similar among groups. The mean MHR was significantly higher only in the A-AION group compared with the NA-AION and control group (p '.001), whereas there was no difference between NA-AION group and control group (p =.110). On receiver operating characteristic analysis, the area under the curve was 0.755, and the best cut- off value was 12.2 with a sensitivity of 72% and a specificity of 80%. An elevated MHR ratio is significantly associated with A-AION and MHR might be used to differentiate A-AION from NA-AION. © 2020 Taylor & Francis Group, LLC.en_US
dc.identifier.doi10.1080/01658107.2020.1733618
dc.identifier.endpage298en_US
dc.identifier.issn0165-8107
dc.identifier.issue5en_US
dc.identifier.scopus2-s2.0-85081904815
dc.identifier.scopusqualityQ3
dc.identifier.startpage294en_US
dc.identifier.urihttps://doi.org/10.1080/01658107.2020.1733618
dc.identifier.volume44en_US
dc.identifier.wosWOS:000527555900001
dc.language.isoenen_US
dc.publisherTaylor and Francis Ltd. michael.wagreich@univie.ac.aten_US
dc.relation.ispartofNeuro-Ophthalmologyen_US
dc.relation.journalNeuro-Ophthalmologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnterior Ischaemic Optic Neuropathyen_US
dc.subjectInflammationen_US
dc.subjectMonocyte to High-Density Lipoprotein Ratioen_US
dc.titleMonocyte to High-Density Lipoprotein Ratio in Patients With Arteritic and Non-Arteritic Anterior Ischaemic Optic Neuropathyen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files